Expression of c-FLIP is primarily detected in diffuse large B-cell lymphoma and Hodgkin's lymphoma and correlates with lack of caspase 8 activation

Histopathology

Volumn 51, Issue 6, 2007, Pages 778-784

  Van Houdt, I S ^a   Muris, J J ^a   Hesselink, A T ^a   Kramer, D ^a   Cillessen, S A G M ^a   Moesbergen, L M ^a   Vos, W ^a   Hooijberg, E ^a   Meijer, C J L M ^a   Kummer, J A ^b   Oudejans, J J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antibodies; Apoptosis; B cell lymphomas; Hodgkin's lymphoma

Indexed keywords

CASPASE 8; FLICE INHIBITORY PROTEIN;

ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; GENETIC TRANSFECTION; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LYMPHOMA;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; ENZYME ACTIVATION; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE;

EID: 36549089970     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02882.x     Document Type: Article

References (30)

1. Poppema S. Immunobiology and pathophysiology of Hodgkin Lymphomas. Hematology 2005 1 231 238.
2. Oscier DG, Gardiner AC. Lymphoid neoplasms. Best Pract Res. Clin. Haematol. 2001 14 609 630.
3. Kishimoto H, Surh CD, Sprent J. A role for Fas in negative selection of thymocytes in vivo. J. Exp. Med. 1998 187 1427 1438.
4. Castro JE, Listman JA, Jacobson BA et al. Fas modulation of apoptosis during negative selection of thymocytes. Immunity 1996 5 617 627.
5. Boatright KM, Salvesen GS. Mechanisms of caspase activation. Current opinion in cell biology 2003. Curr. Opin. Cell Biol. 2003 15 725 731.
6. Wang J, Lobito AA, Shen F, Hornung F, Winoto A, Lenardo MJ. Inhibition of Fas-mediated apoptosis by the B cell antigen receptor through c-FLIP. Eur. J. Immunol. 2000 30 155 163.
7. Hennino A, Berard M, Casamayor-Palleja M, Krammer PH. Regulation of the Fas death pathway by FLICE-inhibitory protein in primary human B cells. J. Immunol. 2000 165 3023 3030.
8. Hennino A, Berard M, Krammer PH, Defrance T. FLICE-inhibitory protein is a key regulator of germinal center B cell apoptosis. J. Exp. Med. 2001 193 447 458.
9. van Eijk M, Medema JP, de Groot C. Cutting edge: cellular Fas-associated death domain-like IL-1-converting enzyme-inhibitory protein protects germinal center B cells from apoptosis during germinal center reactions. J. Immunol. 2001 166 6473 6476.
10. Thome M, Schneider P, Hofmann K et al. Viral FLICE-inhibitory proteins (Flips) prevent apoptosis induced by death receptors. Nature 1997 386 517 521.
11. Scaffidi C, Schmitz I, Krammer PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J. Biol. Chem. 1999 274 541 1548.
12. Chang DW, Xing Z, Pan Y et al. c-FLIP(L) is a dual function regulator for caspase 8 activation and CD95-mediated apoptosis. EMBO J. 2002 21 3704 3714.
13. Boatright KM, Deis C, Denault JB, Sutherlin DP, Salvesen GS. Activation of caspases-8 and -10 by FLIP(L). Biochem. J. 2004 382 651 657.
14. Kataoka T. The caspase 8 modulator c-FLIP. Crit. Rev. Immunol. 2005 25 31 58.
15. Micheau O, Thome M, Schneider P et al. The long form of FLIP is an activator of caspase 8 at the Fas death-inducing signaling complex. J. Biol. Chem. 2002 277 45162 45171.
16. Irmler M, Thome M, Hahne M et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997 388 190 195.
17. Rajewsky K. Clonal selection and learning in the antibody system. Nature 1996 381 751 758.
18. Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumour progression factors. J. Exp. Med. 1999 190 1025 1032.
19. Oyarzo MP, Medeiros LJ, Atwell C et al. c-FLIP confers resistance to fas-mediated apoptosis in anaplastic large cell lymphoma. Blood 2006 107 2544 2547.
20. Valnet-Rabier MB, Challier B, Thiebault S et al. c-Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome. Br. J. Haematol. 2005 128 767 773.
21. Thomas RK, Kallenborn A, Wickenhauser C et al. Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. Am. J. Pathol. 2002 160 1521 1528.
22. Valente G, Manfroi F, Peracchio C et al. c-FLIP expression correlates with tumour progression and patient outcome in non-Hodgkin lymphomas of low grade of malignancy. Br. J. Haematol. 2006 132 560 570.
23. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours. Lyon: IARC Press, 2001.
24. Muris JJ, Meijer CJ, Vos W et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J. Pathol. 2006 208 714 723.
25. Scaffidi C, Medema JP, Krammer PH, Peter ME. FLICE is predominantly expressed as two functionally active isoforms, caspase 8/a and caspase 8/b*. J. Biol. Chem. 1997 272 26953 269538.
26. Mathas S, Lietz A, Anagnostopoulos I et al. c-FLIP mediates resistance of hodgkin/reed-sternberg cells to death receptor-induced apoptosis. J. Exp. Med. 2004 199 1041 1052.
27. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999 18 6853 6866.
28. Sharma S, Grandvaux N, Mamane Y et al. Regulation of IFN regulatory factor 4 expression in human T cell leukemia virus-I-transformed T cells. J. Immunol. 2002 169 3120 3130.
29. Kreuz S, Siegmund D, Scheurich P, Wajant H. NF-kappaB inducers upregulate c-FLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol. Cell. Biol. 2001 21 3964 3973.
30. Muris JJ, Cillessen SA, Vos W et al. Immunohistochemical profiling of caspase signalling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood 2005 105 2916 2923.